Disc Medicine (NASDAQ:IRON) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Disc Medicine (NASDAQ:IRON) from a sell rating to a hold rating in a research note published on Saturday.

Other equities analysts also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Morgan Stanley boosted their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $104.44.

Disc Medicine Trading Down 0.9%

IRON stock opened at $76.31 on Friday. The company’s 50-day simple moving average is $72.93 and its 200-day simple moving average is $69.63. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The firm has a market cap of $2.91 billion, a P/E ratio of -11.60 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. As a group, equities analysts forecast that Disc Medicine will post -6.75 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In related news, COO Jonathan Yen-Wen Yu sold 9,700 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,947,181.84. This represents a 15.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rahul Khara sold 1,649 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $123,675.00. Following the completion of the transaction, the insider directly owned 52,173 shares in the company, valued at $3,912,975. This represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 105,712 shares of company stock valued at $7,597,536 over the last 90 days. Corporate insiders own 3.76% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Disc Medicine in the fourth quarter worth approximately $33,000. KBC Group NV purchased a new stake in shares of Disc Medicine during the fourth quarter worth approximately $80,000. Persistent Asset Partners Ltd acquired a new position in Disc Medicine in the 4th quarter valued at $141,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Disc Medicine by 15,137.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock valued at $161,000 after purchasing an additional 2,422 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.